Needham analyst Serge Belanger maintained a Hold rating on Adamas Pharmaceuticals today. The company’s shares closed last Tuesday at $5.41.

According to, Belanger is a 4-star analyst with an average return of 5.6% and a 46.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamas Pharmaceuticals with a $13.25 average price target.

The company has a one-year high of $9.15 and a one-year low of $2.43. Currently, Adamas Pharmaceuticals has an average volume of 502.1K.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMS in relation to earlier this year. Most recently, in March 2021, John MacPhee, a Director at ADMS bought 192,000 shares for a total of $126,720.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer’s disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.